Cellular plasticity and resilience and the pathophysiology of severe mood disorders by Charney, Dennis S. et al.
epression is a common,chronic,and often dis-
abling psychiatric illness,which is estimated to affect 5%
to 10% of the population.It frequently appears in early
life,has a chronic course,and is considered a risk factor
for other medical illnesses,such as coronary vascular dis-
ease,diabetes,and osteoporosis.This is not altogether sur-
prising given the extensive bidirectional “mind-body”
interactions mediated via the autonomic nervous system,
immune system, and a host of neuroendocrine factors.
According to the World Health Organization (WHO),
depression is the leading global cause of years of life lived
with disability and the fourth leading cause of disability-
adjusted life-years. Disability-adjusted life-years is
defined as the reduction in an individual’s productive life,
and takes into account premature mortality.
1,2
Considering the high morbidity and mortality associated
with depression,it is unfortunate that the psychological
and neurobiological underpinnings of depression have
not been specifically defined.Although major depression
is currently diagnosed by means of a diagnostic system
(Diagnostic and Statistical Manual of Mental Health
Disorders,Fourth Edition [DSM-IV]) based upon phe-
nomenology, this disorder most likely embodies a het-
erogeneous set of disorders with multiple causes.
Therefore,one of the major goals of current and future
research on depression is the development of a diagnos-
tic system based on etiology.
3
This goal is becoming increasingly closer to reality due to
recent progress in the identification of neural circuits,
neurochemicals, and signal transduction mechanisms
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Recent advances in the identification of the neural cir-
cuits, neurochemicals, and signal transduction mecha-
nisms involved in the pathophysiology and treatment of
mood disorders have led to much progress toward
understanding the roles of genetic factors and psy-
chosocial stressors. The monoaminergic neurotransmit-
ter systems have received the most attention, partly
because of the observation that effective antidepressant
drugs exert their primary biochemical effects by regu-
lating intrasynaptic concentrations of serotonin and nor-
epinephrine. Furthermore, the monoaminergic systems
are extensively distributed throughout the network of
limbic, striatal, and prefrontal cortical neuronal circuits
thought to support the behavioral and visceral manifes-
tations of mood disorders. Increasing numbers of neu-
roimaging, neuropathological, and biochemical studies
indicate impairments in cellular plasticity and resilience
in patients who suffer from severe, recurrent mood dis-
orders. In this paper, we describe studies identifying pos-
sible structural, functional, and cellular abnormalities
associated with depressive disorders, which are poten-
tially the cellular underpinnings of these diseases. We
suggest that drugs designed to enhance cellular plastic-
ity and resilience, and attenuate the activity of mal-
adaptive stress-responsive systems, may be useful for the
treatment of severe mood disorders.   
© 2004, LLS SAS Dialogues Clin Neurosci. 2004;6:217-225.underlying the pathophysiology and treatment of depres-
sive illness.
4,5Advances toward specifying the contribu-
tion of genetic factors,
6 psychosocial stressors,
7,8 and
gene–environment interactions to susceptibility to
depression are also taking place.
9,10 It is anticipated that,
in the next few years,combined use of genomic and pro-
teomic strategies to refine complex psychiatric diseases
into mechanism-based subcategories may ultimately
facilitate the matching of specific target-based therapies
to particular markers in certain patient subgroups.
11
Of all brain systems,the monoaminergic neurotransmit-
ter systems have received the greatest attention in neu-
robiological studies of depressive disorders.The implica-
tion of these systems in depression is based on several
observations:(i) effective antidepressant drugs exert their
primary biochemical effects by regulating intrasynaptic
concentrations of serotonin and norepinephrine;and (ii)
antihypertensives that deplete these monoamines some-
times precipitate depressive episodes in susceptible indi-
viduals.
Furthermore,the monoaminergic systems are extensively
distributed throughout the network of limbic,striatal,and
prefrontal cortical (PFC) neuronal circuits implicated in
the behavioral and visceral manifestations of mood disor-
ders.
12 Over the past 40 years,clinical studies have aimed
to uncover specific flaws in these neurotransmitter systems
in mood disorders by using various biochemical and neu-
roendocrine approaches. In fact, assessment of cere-
brospinal fluid (CSF) chemistry,neuroendocrine responses
to pharmacological challenge, and neuroreceptor and
transporter binding have demonstrated a number of
abnormalities of the serotonergic,noradrenergic,and other
neurotransmitter and neuropeptide systems in mood dis-
orders.
Although such studies have been useful in the past,they
have proved to be of limited value in clarifying the par-
ticular pathophysiology of depressive disorders.In order
to clarify the biological underpinnings of these disorders,
there should be an appreciation of the episodic and often
intense mood disturbance,which can become progressive
over the time.Furthermore,the phenotypic expression of
the disease involves not only episodic and often profound
mood disturbances,but also a constellation of cognitive,
motor,autonomic,endocrine,and sleep/wake abnormal-
ities.Additionally,while most antidepressants exert their
initial effects by increasing the levels of serotonin and/or
norepinephrine in the synapse, clinical antidepressant
effects exclusively result after chronic administration
(days to weeks).This suggests that a cascade of down-
stream effects is ultimately responsible for the clinical
antidepressant effects of these medications.These obser-
vations have led to the recognition that, although
monoaminergic neurotransmitter system dysfunction
undoubtedly plays an important role in mediating some
facets of the pathophysiology of depressive disorders,
additional fundamental alterations in cellular plasticity
cascades are most likely involved.
13-15
The functional impairments during mood episodes have
long been recognized; however, there is increasing evi-
dence of significant interepisode impairment as well.The
devastation of these disorders is further complicated by
the fact that the medications currently used for their treat-
ment are associated with variable rates of efficacy and not
intolerable side effects.An appreciation for both the need
for more efficacious treatment for mood disorders and the
absence of significant advances in the development of
truly innovative therapeutics has led to the investigation
of intracellular signaling cascades and their role in the
pathophysiology and treatment of mood disorders.Thus,
while traditionally viewed exclusively as neurochemical
disorders,recent evidence suggests the presence of impair-
ments of cellular plasticity cascades, which produce not
only functional,but also morphological impairments;this
evidence has generated considerable excitement among
the clinical neuroscience community and is reshaping
views about the neurobiological underpinnings of these
disorders.Thus,as we discuss in detail below,increasing
neuroimaging,neuropathological,and biochemical stud-
ies suggest impairments in cellular plasticity and resilience
in patients who suffer from severe,recurrent mood disor-
ders. The term “neuroplasticity” encompasses diverse
essential processes by which the brain perceives,adapts to,
and responds to a variety of internal and external stimuli.
Manifestations of neuroplasticity in the adult central ner-
vous system (CNS) include alterations of dendritic func-
tion,synaptic remodeling,long-term potentiation (LTP),
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Selected abbreviations and acronyms
BDNF brain-derived neurotrophic factor
CREB cyclic adenosine monophosphate (cAMP) response
element binding protein
ERK extracellular response kinase
HPA hypothalamo-pituitary-adrenal (axis)
LTP long-term potentiation
MAP mitogen-activated protein
PFC prefrontal cortexaxonal sprouting,neurite extension,synaptogenesis,and
neurogenesis.In this perspective paper,we describe stud-
ies identifying possible structural,functional,and cellular
abnormalities associated with depressive disorders—the
potential cellular underpinnings of these micro- and
macromorphological brain changes.We suggest that ther-
apeutics designed to enhance cellular plasticity and
resilience, and to attenuate the activity of maladaptive
stress-responsive systems may have considerable utility for
the treatment of severe mood disorders.
Brain imaging studies in depressed patients
Positron emission tomography (PET) imaging studies
have unveiled various abnormalities of glucose metabo-
lism and regional cerebral blood flow (CBF) in limbic and
PFC structures in patients with mood disorders.Although
some disagreement exists regarding the specific locations
and the direction of some of these abnormalities,unmed-
icated subjects with familial major depression show a con-
sistent increase in regional CBF and metabolism in the
amygdala, orbital cortex, and medial thalamus, and
decreased metabolism and CBF in the dorsomedial/dor-
sal anterolateral PFC and anterior cingulate cortex ven-
tral to the genu of the corpus callosum (ie,subgenual PFC)
relative to healthy controls.
16,17These abnormalities suggest
that limbic-thalamic-cortical and limbic-cortical-striatal-
pallidal-thalamic circuits,involving the amygdala,orbital
and medial PFC, and anatomically related parts of the
striatum and thalamus are involved in pathophysiology of
depression.Additionally,these circuits have been impli-
cated more generally in emotional behavior by electro-
physiological,lesion analysis and brain mapping studies of
humans and experimental animals.
12,15
Some of these abnormalities reverse during symptom
remission,suggesting that there are areas where neuro-
physiological activity may increase or decrease in order to
mediate or respond to the emotional and cognitive man-
ifestations of depression.However,CBF and metabolism
do not completely normalize during effective antidepres-
sant treatment in many of these areas.
Morphometric magnetic resonance imaging (MRI) and
postmortem investigations have also demonstrated alter-
ations in cerebral structure that persist regardless of
mood state and may contribute to the corresponding
abnormalities of metabolic activity.
16,17 Structural imaging
studies have shown reduction in gray matter volumes in
areas of the orbital and medial PFC,ventral striatum and
hippocampus, and enlargement of third ventricles in
mood-disordered patients when compared to healthy
controls. Complementary postmortem studies have
demonstrated abnormal decreases in cortex volume,glial
cell counts, and/or neuron size in the subgenual PFC,
orbital cortex, dorsal anterolateral PFC, and amyg-
dala.
12,14,15-17
It remains unclear whether these alterations in brain struc-
ture represent developmental abnormalities that may
increase an individual’s susceptibility to abnormal mood
episodes, compensatory changes to other pathogenic
processes,or the sequelae of recurrent affective episodes
per se.The clarification of these issues will in part depend
on investigations that outline the onset of such abnormal-
ities within the illness course,as well as determine whether
they precede depressive episodes in individuals with a high
familial risk for mood disorders. The lack of complete
reproducibility among neuroimaging or postmortem stud-
ies is not altogether surprising,and the disparities likely
represent variations in experimental design and in patient
populations.Further research is needed in order to under-
stand whether more specifically defined subtypes of
depression or mood disorders are associated with any spe-
cific abnormality.
18The marked reduction in glial cells in
these regions has been especially interesting, given the
tremendous recent progress in our understanding of the
critical roles of glial cells in regulating neuronal function.
Thus, there is now compelling evidence that radial glial
cells have the potential not only to guide newly born neu-
rons,but also to self-renew and to generate both neurons
and astrocytes.Furthermore,recent data have shown that
astrocytes increase the number of mature, functional
synapses on CNS neurons sevenfold,demonstrating that
CNS synapse number can be profoundly regulated by glia.
Glial cells are also known to play critical roles in regulat-
ing synaptic glutamate levels, CNS energy homeostasis,
and the liberation of trophic factors,which in turn partic-
ipate in the development and maintenance of synaptic net-
works formed by neuronal and glial processes.
16,17,19-22 Glial
function abnormalities could thus prove essential to struc-
tural plasticity impairments and overall pathophysiology
of mood disorders.
Stress and brain morphology
The majority of studies of adaptive neuronal plasticity in
response to stress, as well as hypothalamo-pituitary-
adrenal (HPA) axis hormones,have focused on the hip-
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219pocampus.This is partly due to early studies on neuronal
populations of the limbic brain regions,including the den-
tate gyrus granule cell layer,and the CA1 and CA3 pyra-
midal cell layers.These cell layers and their connections
(mossy fiber pathway and Schaffer collateral) have long
been used as cellular models of learning and memory (ie,
LTP).However,it is clear that stress and glucocorticoids
also influence the survival and plasticity of neurons in
other brain regions (such as PFC,vide infra) that have not
yet been studied in the same detail as the hippocampus.
Dendritic remodeling of hippocampal neurons is one of
the best-characterized effects of stress on cellular mor-
phology.
23,24 Dendritic remodeling is deeply observed in the
CA3 pyramidal neurons as atrophy-decreased number and
length of the apical dendritic branches.This stress-induced
atrophy of CA3 neurons results after 2 to 3 weeks of expo-
sure to restraint stress or more long-term social stress,and
has been observed in rodents and tree shrews.
23,24Although
the effects of chronic stress in the CA3 layer tend to be
most pronounced,slight structural changes are also found
in the CA1 and dentate gyrus following a 1-month multi-
ple stress paradigm.
25 Profound alterations in mossy fiber
terminal morphology and significant synapse loss have also
been described.The hippocampus has a very high concen-
tration of glutamate and expresses both glucocorticoid
(GR) and mineralcorticoid (MR) corticosteroid receptors,
though these may be relatively scarce in the hippocampus
of primates,
26,27 and more prevalent in cortical regions.MR
activation in the hippocampus (CA1) is associated with
reduced calcium currents, while GR activation leads 
to increased N-methyl-D-asparate (NMDA) receptor
throughput and increased calcium currents that could pre-
dispose to neurotoxicity.In fact,increasing evidence impli-
cates glutamatergic neurotransmission in stress-induced
hippocampal atrophy and death.
Histopathological changes in rat PFC after corticos-
terone administration have recently been described
although this area has not been as comprehensively stud-
ied as the hippocampus.Using a Golgi-Cox procedure,
Wellman
28 examined pyramidal neurons in layers II and
III of the medial PFC,quantifying dendritic morphology
in three dimensions.In this study,he demonstrated a sig-
nificant rearrangement of apical dendrites in corticos-
terone-treated animals,with an increase in the dendritic
material proximal to the soma and a decrease in distal
dendritic material.This suggests that stress may result in
a significant reorganization of the apical dendritic arbor
in medial PFC in rats.
It is noteworthy that glucocorticoids may exert delete-
rious effects on neural plasticity and morphology,since a
significant percentage of mood disorder patients show
some form of HPA axis activation.It has been hypothe-
sized that the depressive subtypes most frequently asso-
ciated with HPA activation are also the most likely to be
associated with reductions in hippocampal volume.
23
Many patients with Cushing’s disease,in which pituitary
gland adenomas cause cortisol hypersecretion,also show
marked depressive symptoms, as well as hippocampal
atrophy. Moreover,some patients with Cushing’s disease
also show reduced hippocampal volumes, correlating
inversely with plasma cortisol concentrations.Corrective
surgical treatment results in an enlargement of hip-
pocampal volume in proportion to the treatment-associ-
ated decrease in urinary free cortisol concentrations.
29,30
HPA axis hyperactivity in mood disorder patients has
been demonstrated by a variety of techniques/measures,
including increased cortisol levels in plasma (especially
at the circadian nadir),urine,and CSF,increased cortisol
response to adrenocorticotropic hormone (ACTH),
blunted ACTH response to corticotropin-releasing hor-
mone (CRH) challenge,enlarged pituitary and adrenal
glands,and reduced CRH receptor density in the brain
(presumably reflecting a compensatory downregulation
to sustained CRH elevations) at postmortem examina-
tion.In both unipolar and bipolar patients,reduced cor-
ticosteroid receptor feedback has been implicated in this
process by challenge studies with dexamethasone and
dexamethasone plus CRF.
31,32
The results of recent longitudinal studies investigating
the effects of early life stress and inherited variation in
monkey hippocampal volumes underscore the need for
caution when interpreting the clinical neuroimaging stud-
ies described above.These longitudinal studies in mon-
keys randomized paternal half-siblings (monkeys raised
apart from one another by different mothers in the
absence of fathers) to one of three postnatal conditions
that interfered with various facets of early maternal care.
Paternal half-siblings with small adult hippocampal vol-
umes showed an initial larger relative increase in cortisol
level following removal of all mothers after weaning.
33
However, plasma cortisol levels 3 and 7 days later did
correlate with hippocampal size.These studies suggest
that small hippocampal volume also reflects an inherited
trait,and emphasize the need for caution in the simple
attribution of causality in the cross-sectional morpho-
metric studies of the hippocampus in humans.
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and resilience
In addition to the cellular mechanisms described above,
it is now clear that stressors may exert major effects 
on cellular plasticity and resilience by regulating the
expression and function of growth factor cascades.
33,34
Neurotrophic factors (eg, nerve growth factor [NGF]
and brain-derived neurotrophic factor [BDNF]),as well
as cytokines, insulin-like growth factor–1 (IGF-1), and
glial-derived neurotrophic factor (GDNF),increase cell
survival.
35,36 These factors promote cell survival through
the suppression of intrinsic, cellular apoptotic machin-
ery, rather than by inducing cell survival pathways.This
occurs via binding of these factors to membrane recep-
tors and regulation of intracellular signal transduction
pathways that can control apoptosis, including regula-
tion of Bcl-2 family members.Mitogen-activated protein
(MAP) kinase cascade,the phosphatidylinositol-3 kinase
(PI-3K)/Akt pathway, and the PI-3K cascade are cur-
rently thought to be responsible for mediating many of
the effects of neurotrophic factors.
37
The family of receptors known as Trks,which contain an
intrinsic tyrosine kinase domain,mediates neurotrophic
factor signaling. Nerve growth factor binds to the TrkA
receptor, while BDNF binds to TrkB. The resulting
receptor activation results in phosphorylation and acti-
vation of effectors, including PI-3K, as well as protein
coupling leading to of the MAP kinase cascade activa-
tion. Recent studies have shown that MAP kinase cas-
cade activation can inhibit apoptosis by inducing the
phosphorylation of Bad (a major proapoptotic protein)
and increasing the expression of Bcl-2 (a major anti-
apoptotic protein).This increased Bcl-2 expression likely
involves a protein known as the cyclic adenosine
monophosphate (cAMP) response element binding pro-
tein (CREB).
38,39 Phosphorylation of Bad takes place via
activation of a downstream target of the MAP kinase
cascade, ribosomal S-6 kinase (Rsk).This phosphoryla-
tion by Rsk promotes the inactivation of Bad.
Additionally,Rsk activation mediates the actions of the
MAP kinase cascade and neurotrophic factors on the
expression of Bc1-2. Rsk can phosphorylate CREB,
leading to induction of Bcl-2 gene expression.A grow-
ing body of evidence indicates that not only is Bcl-2 neu-
roprotective,but also that it exerts neurotrophic effects
and promotes neurite sprouting,neurite outgrowth,and
axonal regeneration.
40-43
Recently,it has been demonstrated that chronic stress (21
days’ foot-shock) induces a marked and persistent hyper-
phosphorylation of an extracellular response kinase
(ERK) in higher PFC layer dendrites, while phospho-
CREB was reduced in the frontal cortex and other cor-
tical regions.
44 Since CREB is phosphorylated and acti-
vated by phospho-ERK1/2 directly, this reduction
indicates that chronic stress could downregulate CREB
phosphorylation indirectly,and subsequently downregu-
late the transcription of some genes such as Bcl-2 and
BDNF. In this context, it is worth mentioning that a
recent study revealed that severe stress exacerbates
stroke outcome by suppressing Bcl-2 expression.
45 In this
study,stressed mice expressed approximately 70% less
Bcl-2 mRNA than unstressed mice following stroke.In
addition,stress greatly exacerbated stroke in control mice,
but not in transgenic mice that express increased neuronal
Bcl-2.High corticosterone concentrations were signifi-
cantly correlated with a greater stroke size in wild-type
mice, but not in transgenic mice overexpressing Bcl-2.
Therefore,enhanced Bcl-2 expression seems to offset the
potentially harmful consequences of stress-induced neu-
ronal endangerment,and suggests that pharmacologically
induced upregulation of Bcl-2 may be useful in the treat-
ment of a various disorders that have been linked to
endogenous or acquired impairments of cellular
resilience. It is now clear that the neurotrophic fac-
tor–ERK1/2–MAPK–Bcl-2 signaling cascade has a criti-
cal role in cell survival in the CNS and that a fine balance
exists between the levels and activities of cell survival and
cell death factors.BDNF–ERK1/2–CREB–Bcl-2 cascade
dysregulation may be a key mechanism via which pro-
longed stress induces atrophy of select vulnerable neu-
ronal subpopulations,distal dendrites,or both.Although
dysregulation of this cascade most likely results in
decreased neuronal survival,the differential survival is
likely modulated not only by region-specific expression
of protective factors,but also by the network properties
of vulnerable structures.Therefore, it is likely that the
dynamics of the impairments of cellular plasticity and
resilience are determined by intrinsic properties of the
affected regions.
There is emerging evidence—mainly from postmortem
studies—supporting a role for abnormalities in neu-
rotrophic signaling pathways in depression.Decreased lev-
els of CREB, BDNF, and the TrkB receptor have been
described in suicide victims.
46-48 Depressed individuals may
also have genetic abnormalities in CREB and BDNF.
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221Sequence variations in the CREB1 gene have been
observed in depressed women.
6A coding variant of BDNF
may be associated with the personality trait of neuroticism,
which is a risk factor for depression.
49 Furthermore,two
recent studies
50,51 suggest that a polymorphism in the pro-
BDNF molecule is associated with bipolar disorder (a con-
dition in which depressive episodes are accompanied by
manic episodes).This polymorphism is associated with
alterations in BDNF trafficking and secretion in vitro,as
well as with alterations in hippocampal working memory
in humans.
52Therefore,an opportunity exists to study the
interaction of life stress,signal transduction–related genes,
neuroimaging abnormalities consistent with deficient
structural plasticity,and susceptibility to depression.
15
Antidepressant mechanisms and 
neurotrophic signaling cascades
An increasing amount of evidence suggests that antide-
pressants regulate neurotrophic signaling cascades.
Antidepressant treatment increases CREB phosphoryla-
tion and CREB-mediated gene expression in mice limbic
brain regions.
53Various classes of chronic antidepressant
treatments,as well as electroconvulsive treatment (ECT),
upregulate CREB and BDNF expression,suggesting that
the CREB cascade and BDNF are common post-receptor
targets of antidepressants.
54,55This increase is exclusively
seen after chronic use, thus corresponding to the onset
clinical antidepressant effects with these therapies.
Additional evidence that relates upregulation of these
pathways and antidepressant treatment comes from anti-
depressant-like performance in behavioral models.
56 In
rats,CREB overexpression in the dentate gyrus or BDNF
injection leads to an antidepressant-like effect in the
learned-helplessness paradigm and the forced swim test
model of antidepressant efficacy.
57-59
Chronic antidepressant treatment also increases the neu-
rogenesis of dentate gyrus granule cells.
60-62This effect has
not been observed with acute antidepressant treatment.
These studies show that chronic administration of differ-
ent classes of antidepressants and ECT lead to an increase
in the proliferation and survival of new neurons.Lithium,
an effective antidepressant potentiating agent, also
increases neurogenesis in the dentate gyrus.
63 It is note-
worthy that in contrast to the findings seen with chronic
antidepressant use,increases in neurogenesis do not occur
with chronic administration of nonantidepressant psy-
chotropic medications. Increases in neurogenesis have
been reported to occur with conditions that stimulate neu-
ronal activity (eg,enriched environment,learning,exer-
cise).This suggests that neurogenesis is positively regu-
lated by,and might be reliant on,neuronal plasticity.
The enhancement of hippocampal neurogenesis following
chronic antidepressant use highlights the level to which
these efficacious treatments can regulate long-term neu-
roplastic processes in the brain.Since stress and antide-
pressants have opposite effects on hippocampal neuroge-
nesis,it is likely that the clinical symptoms of depression
are related to changes in hippocampal neurogenesis. In
order to assess whether antidepressant-induced hip-
pocampal neurogenesis is functionally relevant,Santarelli
and associates
64 utilized both genetic and radiological
methods to show that disruption of antidepressant-
induced neurogenesis blocked behavioral responses to
antidepressants.In this study,serotonin 1A receptor null
mice were insensitive to the neurogenic and behavioral
effects of fluoxetine, a serotonin selective reuptake
inhibitor.In mice,X-irradiation of the hippocampus pre-
vented the neurogenic and behavioral effects of two
classes of antidepressants.Together, the above findings
suggest that some of the behavioral effects observed with
chronic antidepressant use may be mediated by the stim-
ulation of neurogenesis in the hippocampus.However,as
Kempermann
65 clearly articulated,much more research is
required in order to adequately link changes in adult hip-
pocampal neurogenesis to the pathophysiology and treat-
ment of depression.
Agents capable of reversing the hypothesized impairments
of cellular resilience,reductions in brain volume,and cell
death or atrophy in depression have the potential of
becoming new therapeutic classes of antidepressant drugs.
New molecular targets might include phosphodiesterase
inhibitors that increase CREB phosphorylation, MAP
kinase phosphatase inhibitors that increase expression of
the antiapoptotic protein bcl-2, presynaptic glutamate
receptor subtypes that attenuate glutamate release, α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)
potentiators that increase BDNF expression,and NMDA
antagonists that enhance plasticity and cell survival.
14
Concluding comments
A substantial body of evidence suggests that impairments
in neuroplasticity and cellular resilience play a central role
in the underlying biology of mood disorders.Additionally,
there is a growing appreciation that new medications that
Clinical research
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or indirectly alter monoaminergic throughput,may be of
limited benefit to those patients with refractory depres-
sion.Those strategies assume that the target circuits are
functionally intact and that changes in synaptic activity
will alter the postsynaptic throughput of the system.The
evidence discussed here indicates that,in addition to neu-
rochemical changes,many patients suffering from mood
disorders also have marked structural alterations in cru-
cial neuronal circuits. Therefore, in order to obtain an
optimal treatment response,it will most likely be crucial
to provide both trophic and neurochemical support.The
aim of the trophic support would be to enhance and
maintain normal synaptic connectivity,therefore permit-
ting the chemical signal to restore maximum functioning
of vital circuits essential for normal affective functioning.
In fact,preliminary studies suggest that regional structural
changes in the brains of patients with mood disorders may
be related with not only severity and duration of the ill-
ness, but also with altered treatment response to phar-
macotherapy and ECT.
The evidence also suggests that,somewhat similar to the
treatment of other chronic medical conditions, such as
hypertension and diabetes,prompt and sustained treat-
ment may be necessary to prevent many of the injurious
long-term sequelae associated with mood disorders.
Although the evidence hints at an association between
hippocampal atrophy and illness duration in depressed
patients,it remains unclear whether the volumetric and
cellular changes observed in other brain areas are related
to affective episodes.In fact,some studies have described
reduced gray matter volumes and increased ventricle size
in patients with mood disorders at the time of their first
episode and in early onset of the disease.
12,15
In conclusion,relevant genotypes for mood disorders are
being identified,and clinical research techniques are now
capable of defining neurobiological phenotypes.Similarly,
results from transcriptomic and proteomic studies which
identified neurotrophic signaling as targets for the long-
term actions of antidepressants and mood stabilizers have
played a role (along with neuroimaging and postmortem
brain studies) in a reconceptualization about the patho-
physiology, course, and optimal long-term treatment of
severe mood disorders. These data suggest that, while
mood disorders are clearly not classical neurodegenera-
tive diseases,they are in fact associated with impairments
of cellular plasticity and resilience.As a consequence,there
is a growing appreciation that optimal long-term treatment
will most likely be achieved by attempting to prevent the
underlying disease progression and its attendant cellular
dysfunction,rather than exclusively focusing on the treat-
ment of signs and symptoms.We are optimistic that a new
generation of research will clarify the relation among envi-
ronmental and genetic risk factors to quantify the risk for
the development of depression more precisely. These
advances will result in a dramatically different diagnostic
system based upon etiology,and ultimately in the discov-
ery of new approaches to the prevention and treatment of
some of mankind’s most devastating and least understood
illnesses. ❏
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Plasticidad celular, resiliencia y fisiopatología
de los trastornos afectivos graves
Los avances recientes en la identificación de los cir-
cuitos neurales, los mecanismos neuroquímicos y de
transducción de señales que participan en la fisiopa-
tología y el tratamiento de los trastornos afectivos
han conducido hacia un significativo progreso en la
comprensión de los papeles de los factores genéticos
y de los estresores psicosociales. Los sistemas de neu-
rotransmisión monoaminérgica han concitado la
mayor atención, en parte, debido a la observación
que los antidepresivos eficaces ejercen sus efectos
bioquímicos primarios a través de la regulación de
las concentraciones intrasinápticas de serotonina y
noradrenalina. Además, los sistemas monoaminér-
gicos se distribuyen extensamente a través de la red
de circuitos neuronales límbicos, estriatales y corti-
cales prefrontales, que se piensa son los responables
de las manifestaciones conductuales y viscerales de
los trastornos afectivos. Un número creciente de
estudios de neuroimágenes, neuropatológicos y bio-
químicos revelan deterioros en la plasticidad celular
y la resiliencia en pacientes que padecen trastornos
afectivos graves y recurrentes. En este artículo se des-
criben estudios que identifican posibles anormalida-
des estructurales, funcionales y celulares que se 
asocian con los trastornos depresivos, los que consti-
tuyen potencialmente los fundamentos celulares de
estas enfermedades. Se sugiere que los fármacos
diseñados para incrementar la plasticidad celular y la
resiliencia, y atenuar la actividad de los sistemas que
determinan una mala adaptación al estrés, pueden
ser útiles para el tratamiento de los trastornos afec-
tivos graves.
Plasticité cellulaire, résilience et 
physiopathologie des troubles de l’humeur
sévères
Les progrès récents concernant l’identification des sub-
stances chimiques et circuits neuronaux et des méca-
nismes de transduction du signal impliqués dans la phy-
siopathologie et le traitement des troubles de l’humeur
ont amélioré la compréhension des rôles des facteurs
génétiques et des facteurs psychosociaux de stress. Les
systèmes de neurotransmetteurs monoaminergiques ont
retenu le plus d’attention, en partie parce que l’on a
remarqué que les principaux effets biochimiques des anti-
dépresseurs efficaces s’exercent en régulant les concen-
trations intrasynaptiques de sérotonine et noradrénaline.
De plus, les systèmes monoaminergiques sont largement
distribués dans le réseau des circuits neuronaux lim-
biques, striataux et du cortex préfrontal supposés déter-
miner les manifestations comportementales et orga-
niques des troubles de l’humeur. De plus en plus d’études
de neuro-imagerie, neuropathologie et biochimie souli-
gnent l’altération de la plasticité cellulaire et de la rési-
lience chez les patients souffrant de troubles de l’humeur
sévères et récurrents. Dans cet article, nous décrivons des
études identifiant de possibles anomalies structurelles,
fonctionnelles et cellulaires associées aux troubles dépres-
sifs, qui constituent les bases cellulaires potentielles de
ces pathologies. Nous suggérons que les médicaments
conçus pour augmenter la plasticité cellulaire et la rési-
lience et atténuer l’activité des systèmes inadaptés de
réponse aux stress pourraient être utiles au traitement
des troubles de l’humeur sévères.
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